SPI Pharma: From Decades of Alum Leadership to Next-Generation Vaccine Solutions

11/16/2026

For more than two decades, SPI Pharma has been a trusted supplier of high-quality aluminum hydroxide vaccine adjuvants. Building on more than 70 years of expertise in aluminum hydroxide chemistry, the company has supplied alum-based adjuvants used in commercial vaccines worldwide. Although historically stronger in the veterinary market through its VAC range, SPI Pharma is now making a deliberate and expansive push into human health, investing in technology, capacity, and strategic partnerships to deliver a broader, more sophisticated adjuvant toolbox.

Aluminum hydroxide remains the most widely used and studied adjuvant chemistry globally, prized for its safety profile, antigen adsorption performance, and regulatory familiarity. SPI Pharma’s long manufacturing experience has given it deep process knowledge around consistency in morphology, particle size, protein adsorption capacity, and compliance withmonograph standards. That foundation is now being leveraged for human applications under the Valens™ brand while the VAC portfolio continues to serve animal health with expanded grade options.

The Valens™ Brand and Human Health Expansion

August 2025, SPI Pharma launched the Valens™ portfolio brand (from the Latin for “strong, vigorous, and healthy”) to group its vaccine adjuvants, parenteral excipients, and related materials for the biologics and human vaccine markets. The brand differentiates these higher-value offerings from the company’s broader pharmaceutical and consumer health portfolio while signaling a focused growth strategy.

Under Valens™ AH, SPI Pharma has expanded its aluminum hydroxide grades specifically for human vaccines (including concentrations such as AH 1.5, AH 2.0, and AH 3.0). These grades offer formulation flexibility—different alumconcentrations and particle-size—while maintaining the well-characterized adsorption properties and scalable cGMP manufacturing that customers expect.. The company is also investing in manufacturing capabilities, including upgrades at its long-standing French site in Septèmes-les-Vallons, to meet human-vaccine quality standards and increase capacity.

SPI Pharma positions these developments as part of a broader mission: making advanced, stable, and supply-secure adjuvants more accessible to vaccine developers worldwide. By combining its own alum manufacturing expertise with partner technologies in sustainable saponins and synthetic TLR4 agonist, the company aims to offer both single components and ready-to-use systems that can be tailored to specific immunogenicity needs—from traditional antibody-focused responses to more balanced cellular immunity.